Trump announces drug pricing deal with Pfizer

30.09.25 20:35 Uhr

Werte in diesem Artikel
Aktien

21,68 EUR 1,39 EUR 6,85%

Indizes

PKT PKT

17.986,3 PKT 78,6 PKT 0,44%

3.331,7 PKT 13,9 PKT 0,42%

6.688,5 PKT 27,3 PKT 0,41%

President Donald Trump announced on Tuesday a drug pricing deal with Pfizer that will see the pharmaceutical giant lower the cost of its medications for Americans.Trump made the announcement from the Oval Office at the White House, saying that Pfizer has committed to offering its prescription medications to Medicaid at the reduced "most favored nation prices.""Pfizer is agreeing to provide some of their most popular current medications to all consumers at heavily discounted prices of anywhere between 50% and even 100%. And that's off, that's off the price. And in some cases, even more than that."The president added that the U.S. "is done subsidizing the health care of the rest of the world."TRUMP'S QUEST TO REDUCE DRUG PRICES IS HEATING UP. BUT WILL HE BE ABLE TO DO IT?Trump said the drugs will be available for direct purchase online at a website run by the federal government. The website is called TrumpRx and would be launched soon, said Chris Klomp, Director of Medicare and an adviser to Health and Human Services Secretary Robert F. Kennedy Jr.RFK JR ANNOUNCES ‘HISTORIC CRACKDOWN’ ON ‘BROKEN’ ORGAN DONATION SYSTEMTrump also announced that Pfizer would invest $70 billion in manufacturing facilities to produce its drugs in the U.S. Under the terms of the deal, Pfizer will get a three-year grace period where it would not be subject to tariffs as long as it moves the production of its products to American shores.Pfizer CEO Albert Bourla called it an historic day that is "reversing an unfair situation" that has plagued consumers for years."The big winner of this deal clearly will be the American place," Bourla said. "There is no doubt about it. They are the ones that will see significant impact in their ability to buy medicines."GET FOX BUSINESS ON THE GO BY CLICKING HERETrump said that his administration is working with other pharmaceutical companies to secure similar agreements.Weiter zum vollständigen Artikel bei FOX Business

In eigener Sache

Übrigens: Pfizer und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Pfizer

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Pfizer

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: FOX Business

Nachrichten zu Pfizer Inc.

Wer­bung

Analysen zu Pfizer Inc.

DatumRatingAnalyst
30.09.2025Pfizer NeutralJP Morgan Chase & Co.
24.09.2025Pfizer BuyJefferies & Company Inc.
22.09.2025Pfizer NeutralJP Morgan Chase & Co.
17.09.2025Pfizer HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
06.08.2025Pfizer KaufenDZ BANK
DatumRatingAnalyst
24.09.2025Pfizer BuyJefferies & Company Inc.
06.08.2025Pfizer KaufenDZ BANK
21.05.2025Pfizer BuyJefferies & Company Inc.
30.04.2025Pfizer BuyJefferies & Company Inc.
14.04.2025Pfizer BuyJefferies & Company Inc.
DatumRatingAnalyst
30.09.2025Pfizer NeutralJP Morgan Chase & Co.
22.09.2025Pfizer NeutralJP Morgan Chase & Co.
17.09.2025Pfizer HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.08.2025Pfizer NeutralUBS AG
05.08.2025Pfizer NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
03.05.2018Pfizer VerkaufenDZ BANK
16.05.2017Pfizer SellCitigroup Corp.
27.11.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
28.08.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
10.01.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pfizer Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen